RxDoctor Payments Data

Tamera Ostenaa, APRN

Family · Mahnomen, MNNPI 1013483692

Payments from drug & device makers

$234in general payments, 2019–2025

Across 16 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$37
  • Lilly USA, LLC$29
  • Sanofi-aventis U.S. LLC$28
  • Phathom Pharmaceuticals, Inc.$28
  • AstraZeneca$28
  • Lundbeck LLC$16
  • plus $69 from 5 others

What the payments were for

  • Food & beverage$234100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$234 in reported general payments places this provider in the 70th percentile of 1,121 family providers in Minnesota.

See all family providers in Minnesota

Medicare billing

Part B allowed, 2024
$227
Medicare patients
33
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$76,462
JardianceEmpagliflozin55$44,903
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,522
DepakoteDivalproex Sodium12$18,369
TrulicityDulaglutide15$14,812
Soliqua 100-33Insulin Glargine/Lixisenatide14$14,602
MounjaroTirzepatide12$12,664
XareltoRivaroxaban18$12,105
Incruse ElliptaUmeclidinium Bromide27$11,031
TegretolCarbamazepine14$8,454
FarxigaDapagliflozin Propanediol12$6,758
JanumetSitagliptin Phos/Metformin Hcl12$6,711
Victoza 2-PakLiraglutide12$6,134
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,105
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$3,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$29$27,47627 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$28$14,60214 claims
AstraZenecaFarxiga$28$6,75812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,121 family providers in Minnesota.

Other family in Mahnomen

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →